Enjoy Group (HK) Co Ltd
請輸入包含最少兩個字母或數字的關鍵字。
描述
聯絡供應商
描述
- COVID-19 Diagnosis and Treatment Plan (Trial Version 7)
- IgM/IgG antibody test is included in the diagnostic criteria!
- On March 3, 2020, the National Health Commission of the People's Republic of China issued
- "COVID-19 Diagnosis and Treatment Plan (Trial Version 7)n and interpreted it. The latest diagnostic
- Explain the "clustered disease cases" in epidemiology; that is, "2 or more cases of fever and/or respiratory symptoms in a small area such as family; office, school class, etc. within 2 weeks."
- The "decreased lymphocyte count" in clinical manifestations is replaced with "normal or decreased lymphocyte count."
- On the basis of nucleic acid test and sequencing, "serological test" is newly added for disease case determination, that is, wSARS-CoV-2 specific IgM antibodies and IgG antibodies are positive" or"SARS-CoV-2 specific IgG antibodies are changed from negative to positive, or increased by 4 times or higher in recovery phase compared with acute phase" is applicable to disease determination.
- In addition, serological test has been added to clinical manifestations: SARS-CoV-2 specific IgM antibodies are mostly positive after 3~5 days of onset; IgG antibody titer is increased by 4 times or higher during recovery phase compared with acute phase.
- Source: Central People's Government of the People's Republic of China
- http://www.gov.cn
- IgM and IgG are the first antibodies appearing in the human immune system during infection. When detecting acute SARS-CoV-2 infection, IgM and IgG antibodies have the advantages of high sensitivity, early diagnosis, and the ability to judge whether a suspect is infected.
- IgM and IgG antibodies can only be produced after several days of viral infection, and the specific time may vary between individuals.
- Port: Multiple locations can be specified
您或許喜歡
確定要取消關注此供應商？